Journal article
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12
Abstract
The treatment of transformed indolent lymphoma (TRIL) often includes salvage chemotherapy (SC) and autologous stem cell transplant (ASCT). NCIC CTG LY12 is a randomized phase 3 trial comparing gemcitabine, dexamethasone, and cisplatin (GDP) with dexamethasone, cytarabine, and cisplatin (DHAP) before ASCT. This analysis compares the results of SC and ASCT for TRIL with de novo diffuse large B-cell lymphoma (DLBCL). Six-hundred nineteen patients …
Authors
Kuruvilla J; MacDonald DA; Kouroukis CT; Cheung M; Olney HJ; Turner AR; Anglin P; Seftel M; Ismail WS; Luminari S
Journal
Blood, Vol. 126, No. 6, pp. 733–738
Publisher
American Society of Hematology
Publication Date
August 6, 2015
DOI
10.1182/blood-2015-01-622084
ISSN
0006-4971
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinCytarabineDeoxycytidineDexamethasoneEtoposideFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedMultivariate AnalysisPrognosisRecurrenceSalvage TherapySurvival AnalysisTime FactorsTransplantation, AutologousGemcitabine